A Downside To the Myth Of BIBW2992 Exposed

Pooled analysis of the results from the completed RE-MOBLIZE, RE-MODEL and RE-NOVATE phase III trials, which involved a combined total of 8?210 patients, concluded that dabigatran etexilate is as efficacious and safe as enoxaparin in the prevention of VTE after hip or knee arthroplasty [53]. Two different doses of dabigatran etexilate, 150?mg or 220?mg once daily with half doses, 75?mg or 110?mg, on the first day were examined and compared against the approved enoxparin regimen for the respective region in all three trials. RE-MODEL and RE-NOVATE, both performed in the European Union and other non-North American countries, found both doses of dabigatran non-inferior to enoxaparin (40?mg, 12?h presurgery). Rates of total http://www.selleckchem.com/products/BIBW2992.html VTE and all-cause mortality were 36.4% http://www.selleckchem.com/products/BKM-120.html (P http://en.wikipedia.org/wiki/SWAP70 This double-blind, non-inferiority trial examined 2055 patients in North America with a goal to evaluate the efficacy of dabigatran 220?mg once daily vs. enoxaparin 40?mg once daily over a course of 28�C35 days for VTE prevention post-hip replacement surgery. Dabigatran was found to be at least as effective as enoxaparin in preventing total VTE and all-cause mortality (7.7% vs. 8.8%, P